Increased cardiovascular risk in thyroid cancer patients taking levothyroxine: a nationwide cohort study in Korea

in European Journal of Endocrinology
Correspondence should be addressed to Y Park; Email: davidympark@gmail.com

*(B Suh and D W Shin contributed equally to this work)

Restricted access

24-hour access to this article

USD $30.00

Objective

Many thyroid cancer patients are exposed to long-term thyroid-stimulating hormone (TSH) suppression, often as lifetime treatment, and are consequently at risk for cardiovascular disease. We investigated the incidence of coronary heart disease (CHD) and ischemic stroke among thyroid cancer patients compared with matched control subjects.

Design

Retrospective cohort study.

Methods

A total of 182 419 subjects who received thyroidectomy for thyroid cancer during 2004–2012 were selected from the Korean National Health Insurance data, which cover approximately 97% of the entire Korean population. Propensity score matching was used to select non-cancer controls. Cox proportional hazards regression analysis was used to determine relative risk of coronary heart disease and ischemic stroke. Mean follow-up was 4.32 years.

Results

Thyroid cancer patients had elevated risk for CHD and ischemic stroke with hazard ratio (HR) of 1.15 (95% confidence interval (CI): 1.10–1.22) and 1.15 (1.09–1.22), respectively. This risk was increased in those who took a higher dosage of levothyroxine (HR: 1.47, 95% CI: 1.34–1.60 for CHD and HR: 1.56, 95% CI: 1.42–1.72 for ischemic stroke among those who took ≥170 μg/day levothyroxine). Although risk of atrial fibrillation was dose-dependently associated with levothyroxine dosage, it represents only a small proportion of ischemic stroke incidence (4.4%, 128/2914).

Conclusions

The risk for CHD and ischemic stroke was higher in thyroid cancer patients who received thyroidectomy, and the dosage of levothyroxine administered appears to play a major role. Greater caution is suggested for the screening and treatment of thyroid cancer and subsequent TSH suppression therapy, as well as proper management for cardiovascular disease prevention.

 

Official journal of

European Society of Endocrinology

Sections

Figures

  • View in gallery

    Selection scheme for study population.

  • View in gallery

    Kaplan–Meier curves for incidence of coronary heart disease and ischemic stroke among thyroid cancer patients. Kaplan–Meier curves for coronary heart disease incidence (Panel A) and ischemic stroke incidence (Panel B), where post-thyroidectomy thyroid cancer patients (case) are compared to matched controls. P values indicate results from log-rank tests.

  • View in gallery

    Forest plots for coronary heart disease and ischemic stroke incidence among thyroid cancer patients and matched controls. Hazard ratios were determined by univariable Cox proportional hazards regression analysis of specific case subjects compared to individually matched controls. Rates are indicated per 1000 person-years. LT4, levothyroxine; TT, total thyroidectomy; UL, unilateral lobectomy.

  • View in gallery

    Involvement of atrial fibrillation in risk of ischemic stroke incidence among thyroid cancer patients. Hazard ratios were determined by multivariable Cox proportional hazards regression analysis adjusted by age, sex, hypertension, diabetes, and dyslipidemia. Rate is indicated per 1000 person-years. Afib, atrial fibrillation; LT4, levothyroxine.

References

1

American Thyroid Association Guidelines Taskforce on Thyroid NDifferentiated Thyroid CCooperDSDohertyGMHaugenBRKloosRTLeeSLMandelSJMazzaferriELMcIverBPaciniFSchlumbergerM et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009 19 11671214. (https://doi.org/10.1089/thy.2009.0110)

2

PaciniFSchlumbergerMDralleHEliseiRSmitJWWiersingaW. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology 2006 154 787803. (https://doi.org/10.1530/eje.1.02158)

3

SawinCTGellerAWolfPABelangerAJBakerEBacharachPWilsonPBenjaminEJD’AgostinoRB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. New England Journal of Medicine 1994 331 12491252. (https://doi.org/10.1056/NEJM199411103311901)

4

DörrMEmpenKRobinsonDMWallaschofskiHFelixSBVölzkeH. The association of thyroid function with carotid artery plaque burden and strokes in a population-based sample from a previously iodine-deficient area. European Journal of Endocrinology 2008 159 145152. (https://doi.org/10.1530/EJE-08-0140)

5

PetersAEhlersMBlankBExlerDFalkCKohlmannTFruehwald-SchultesBWellhoenerPKernerWFehmHL. Excess triiodothyronine as a risk factor of coronary events. Archives of Internal Medicine 2000 160 19931999.

6

BiondiBCooperDS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010 20 135146. (https://doi.org/10.1089/thy.2009.0311)

7

AbonowaraAQuraishiASappJLAlqambarMHSaricAO’ConnellCMRajaramanMMHartRDImranSA. Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer. Clinical and Investigative Medicine 2012 35 E152E156. (https://doi.org/10.25011/cim.v35i3.16591)

8

SmitJEustatia-RuttenCCorssmitEPereiraAFrolichMBleekerGHolmanEVan Der WallERomijnJBaxJ. Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism 2005 90 60416047. (https://doi.org/10.1210/jc.2005-0620)

9

ShargorodskyMSerovSGavishDLeibovitzEHarpazDZimlichmanR. Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma. Thyroid 2006 16 381386. (https://doi.org/10.1089/thy.2006.16.381)

10

HesselinkENKHesselinkMSKde BockGHGansevoortRTBakkerSJVredeveldEJvan der Horst-SchriversANvan der HorstICKamphuisenPWPlukkerJT. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. Journal of Clinical Oncology 2013 31 40464053. (https://doi.org/10.1200/JCO.2013.49.1043)

11

PajamakiNMetsoSHakalaTEbelingTHuhtalaHRyodiESandJJukkola-VuorinenAKellokumpu-LehtinenPLJaatinenP. Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer. Clinical Endocrinology 2018 88 303310. (https://doi.org/10.1111/cen.13519)

12

SeongSCKimYYKhangYHHeon ParkJKangHJLeeHDoCHSongJSHyon BangJHaS et al. Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea. International Journal of Epidemiology 2016 46 799800. (https://doi.org/10.1093/ije/dyw253)

13

ShinDWChoBGuallar E.Korean National Health Insurance database. JAMA Internal Medicine 2016 176 138138. (https://doi.org/10.1001/jamainternmed.2015.7110)

14

ShinDWSuhBLimHYunJMSongSOParkY. J-shaped association between postoperative levothyroxine dosage and fracture risk in thyroid cancer patients: a retrospective cohort study. Journal of Bone and Mineral Research 2018 33 10371043. (https://doi.org/10.1002/jbmr.3407)

15

RubinDB. On principles for modeling propensity scores in medical research. Pharmacoepidemiology and Drug Safety 2004 13 855857. (https://doi.org/10.1002/pds.968)

16

LeeHChoJShinDWLeeSPHwangSSOhJYangHKHwangSHSonKYChunSH et al. Association of cardiovascular health screening with mortality, clinical outcomes, and health care cost: a nationwide cohort study. Preventive Medicine 2015 70 1925. (https://doi.org/10.1016/j.ypmed.2014.11.007)

17

BiondiBCooperDS. The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews 2008 29 76131. (https://doi.org/10.1210/er.2006-0043)

18

DevdharMDroogerRPehlivanovaMSinghGJonklaasJ. Levothyroxine replacement doses are affected by gender and weight, but not age. Thyroid 2011 21 821827. (https://doi.org/10.1089/thy.2011.0029)

19

HaugenBRAlexanderEKBibleKCDohertyGMMandelSJNikiforovYEPaciniFRandolphGWSawkaAMSchlumbergerM. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016 26 1133. (https://doi.org/10.1089/thy.2015.0020)

20

U. S. Preventive Services Task ForceBibbins-DomingoKGrossmanDCCurrySJBarryMJDavidsonKWDoubeniCAEplingJWJrKemperARKristAHKurthAE et al. Screening for thyroid cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2017 317 18821887. (https://doi.org/10.1001/jama.2017.4011)

21

SundaramVHannaANKoneruLNewmanHAFalkoJM. Both hypothyroidism and hyperthyroidism enhance low density lipoprotein oxidation. Journal of Clinical Endocrinology and Metabolism 1997 82 34213424.

22

SheuJJKangJHLin HC & Lin HC. Hyperthyroidism and risk of ischemic stroke in young adults: a 5-year follow-up study. Stroke 2010 41 961966. (https://doi.org/10.1161/STROKEAHA.109.577742)

23

ColletTHGusseklooJBauerDCden ElzenWPCappolaARBalmerPIervasiGAsvoldBOSgarbiJAVolzkeH et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Archives of Internal Medicine 2012 172 799809.

24

SquizzatoAGerdesVEBrandjesDPBullerHRStamJ. Thyroid diseases and cerebrovascular disease. Stroke 2005 36 23022310. (https://doi.org/10.1161/01.STR.0000181772.78492.07)

25

JanuaryCTCalkinsHMurrayKTCigarroaJEStevensonWG. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation. Circulation 2014 129 20712104. (https://doi.org/10.1161/CIR.0000000000000040)

26

CammAJLipGYDe CaterinaRSavelievaIAtarDHohnloserSHHindricksGKirchhofPBaxJJBaumgartnerH. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. European Heart Journal 2012 33 27192747. (https://doi.org/10.1093/eurheartj/ehs253)

27

FlynnRWBonellieSRJungRTMacDonaldTMMorrisADLeeseGP. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. Journal of Clinical Endocrinology and Metabolism 2010 95 186193. (https://doi.org/10.1210/jc.2009-1625)

28

O’BrienTDinneenSFO’BrienPCPalumboPJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clinic Proceedings 1993 68 860866.

29

FommeiEIervasiG. The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. Journal of Clinical Endocrinology and Metabolism 2002 87 19962000. (https://doi.org/10.1210/jcem.87.5.8464)

30

KandanSRSahaM. Severe primary hypothyroidism presenting with torsades de pointes. BMJ Case Reports 2012 2012.

31

DaviesLWelchHG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006 295 21642167. (https://doi.org/10.1001/jama.295.18.2164)

32

AhnHSKimHJWelchHG. Korea’s thyroid-cancer “epidemic” – screening and overdiagnosis. New England Journal of Medicine 2014 371 17651767. (https://doi.org/10.1056/NEJMp1409841)

33

EssermanLJThompsonIMReidBNelsonPRansohoffDFWelchHGHwangSBerryDAKinzlerKWBlackWC. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncology 2014 15 e234e242. (https://doi.org/10.1016/S1470-2045(13)70598-9)

34

ParkSOhCMChoHLeeJYJungKWJunJKWonYJKongHJChoiKSLeeYJ et al. Association between screening and the thyroid cancer “epidemic” in South Korea: evidence from a nationwide study. BMJ 2016 355 i5745. (https://doi.org/10.1136/bmj.i5745)

35

ChoBYChoiHSParkYJLimJAAhnHYLeeEKKimKWYiKHChungJKYounYK et al. Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades. Thyroid 2013 23 797804. (https://doi.org/10.1089/thy.2012.0329)

Index Card

PubMed

Google Scholar

Related Articles

Altmetrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 91 91 91
Full Text Views 100 100 100
PDF Downloads 44 44 44